Welcome back to another edition of Endpoints Weekly. Thanks to everyone who came out to our AI Day event this week in New ...
Eli Lilly's neuroscience president Carole Ho expressed interest in ibogaine R&D at NYC's Psychedelic Healthcare Forum, ...
China's Commerce Ministry proposes restricting export of cell/gene therapy, siRNA, and pathogen tech, while preserving drug ...
Research shows 952K+ US clinicians made 271M queries to AI tool OpenEvidence from Jan 2024–June 2026. But there are concerns ...
Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing “strategic considerations,” according to a ...
More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’s Endpoints 11 ...
NorthStar/Quarkmed, Lonza/Qurient CDK7 deal, Triastek/J&J 3D printing pact, Scinai's $5.1M deal & HydRegen's $8M Series A led ...
OMass has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the ...
Paul Stoffels’ new Armed Cell Therapeutics buys Lakefront’s (ex-Galapagos) preclinical CAR-T work for $9M upfront, $230M in ...
Sanofi's new R&D chief said on Wednesday Western drugmakers cannot ignore China's accelerating innovation and should consider ...
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...
FDA launches Rare Disease Framework Initiative to tailor reviews by disease, with a stakeholder meeting set for Oct. 28.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results